Forth Therapeutics (Forth Tx), a biotechnology company advancing next-generation precision therapeutics for fibrosis, launches today with backing from Sofinnova Partners, a leading European life ...

Cutting-edge research from Professor Neil Henderson at the University of Edinburgh Led by CEO Alex Leech, Partner at Sofinnova Partners Created through Sofinnova's €165M Biovelocita ...

SINGAPORE: A new study from Duke-NUS Medical School has identified a promising new avenue for tackling pulmonary fibrosis, a ...

A recent review published in the journal Engineering delves into the significant advancements and potential of CRISPR ...

However, in a preclinical model of pulmonary fibrosis, the researchers ... immune cells that help to repair and regenerate damaged tissue outnumber their inflammatory counterparts, reducing ...

Research identifies how viral respiratory infection damages macrophages and suggests treatment with a pre-existing FDA approved drug.

The findings of what the Weizmann Institute researchers describe as "hot fibrosis" and "cold fibrosis" were recently published in the peer-reviewed journal Cell Systems.

A new review in Engineering reveals that CRISPR technologies are revolutionizing regenerative medicine. Scientists from ...

While diet does play a role in liver health, experts believe that diets high in saturated fats are linked to liver ...

Since heart muscle cells don't regenerate, the repair consists of cobbling together ... Yet despite the seeming simplicity of scar tissue, fibrosis is, in fact, an extremely complex process ...

control cell fate for tissue repair, and enhance tissue functions. For example, in the treatment of monogenic diseases like cystic fibrosis, sickle cell disease, and osteogenesis imperfecta ...